Cancer Studies
Cancer prevention
-
Preclinical and early clinical development of novel cancer chemopreventive agents
-
Identification and development of novel biomarkers of cancer risk, prognosis and chemopreventive/chemotherapeutic agent efficacy
-
Translation of candidate biomarkers to clinical use.
-
Use of high resolution LC-MS in the discovery and verification of biomarkers.
-
Investigation of protein quantification using Ion mobility.
-
Translation of candidate biomarkers to clinical use.
-
Use of high resolution LC-MS in the discovery and verification of biomarkers.
-
Investigation of protein quantification using Ion mobility.
-
Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
-
Investigating and exploiting metabolic vulnerabilities in carcinogenesis
-
Using circulating cell-free DNA for early detection of cancer
-
The design and delivery of early phase clinical studies including chemoprevention strategies
-
Improving information exchange in oncology consultations
-
Determine which repetitive elements are active in precancerous and cancerous cells
-
Understanding what causes activation of repetitive elements
-
Establish activation of which repetitive elements plays functional roles in cancer
-
Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy
Liquid biopsy for early detection and stratification of cancer
-
Molecular cytogenetics of lymphoid malignancies
-
Antibody therapy of lymphoid malignancies
-
Development and assessment of novel agents for therapy of B-cell malignancies
-
Analysis of circulating cancer biomarkers through liquid biopsy
-
Molecular approaches to aid early detection of cancer
-
Molecular mechanisms of resistance to targeted therapy
-
Analysis of circulating cancer biomarkers through liquid biopsy
-
Molecular approaches to aid early detection of cancer
-
Molecular mechanisms of resistance to targeted therapy
-
Utility of artificial intelligence for early detection and improving therapy stratification
-
Analysis of circulating endometrial cancer biomarkers through liquid biopsy
-
Robotic surgery for management of endometrial cancer
-
Patient-initiated follow up for low-risk endometrial cancer
-
Use of ex-vivo models for personalising therapies
-
Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
-
Investigating and exploiting metabolic vulnerabilities in carcinogenesis
-
Using circulating cell-free DNA for early detection of cancer
Personalised treatment in B cell malignancies
-
Molecular cytogenetics of lymphoid malignancies
-
Antibody therapy of lymphoid malignancies
-
Development and assessment of novel agents for therapy of B-cell malignancies
-
Delivery of Phase I portfolio across haematological malignancies and solid tumours
-
Therapeutic drug development
-
Development and assessment of novel agents in the treatment of B-cell malignancies
-
Developing new diagnostic and therapeutic approaches in T-cell lymphoma
-
Targeting the microenvironment in B-cell lymphoma
Personalised medicine
-
Analysis of circulating cancer biomarkers through liquid biopsy
-
Molecular approaches to aid early detection of cancer
-
Molecular mechanisms of resistance to targeted therapy
-
Analysis of circulating cancer biomarkers through liquid biopsy
-
Molecular approaches to aid early detection of cancer
-
Molecular mechanisms of resistance to targeted therapy
-
Utility of artificial intelligence for early detection and improving therapy stratification
-
Molecular cytogenetics of lymphoid malignancies
-
Antibody therapy of lymphoid malignancies
-
Development and assessment of novel agents for therapy of B-cell malignancies
-
Translation of candidate biomarkers to clinical use.
-
Use of high resolution LC-MS in the discovery and verification of biomarkers.
-
Investigation of protein quantification using Ion mobility.
-
Translation of candidate biomarkers to clinical use.
-
Use of high resolution LC-MS in the discovery and verification of biomarkers.
-
Investigation of protein quantification using Ion mobility.
-
Imaging applications to monitor drug therapy
-
Imaging in cancer research trials including CT, MRI, Ultrasound and PET-CT
-
Discovering and exploiting novel synthetic lethal interactions for targeting tumour suppressor in-activations in thoracic cancers
- Personalising breast cancer treatment according to predicted toxicity
- Radiogenomics and biomarkers
- Breast surgery and reconstuction
- Patients' views on breast cancer treatment and predictive testing
-
The design and delivery of early phase clinical studies including chemoprevention strategies
-
Improving information exchange in oncology consultations
- Delivery of Phase I portfolio across haematological malignancies and solid tumour
- Therapeutic drug development
- Development and assessment of novel agents in the treatment of B-cell malignancies
Pre clinical models enabling drug and biomarker discovery
-
Molecular cytogenetics of lymphoid malignancies
-
Antibody therapy of lymphoid malignancies
-
Development and assessment of novel agents for therapy of B-cell malignancies
-
The design and delivery of early phase clinical studies including chemoprevention strategies
-
Improving information exchange in oncology consultations
-
Mechanisms of RAS/RAF oncogene induced tumour development
-
RAF/MAPK signalling in normal and cancer cells
-
Ex vivo patient relevant drug testing platforms
-
Analysis of circulating endometrial cancer biomarkers through liquid biopsy
-
Molecular profiling for improved stratification to immunotherapies
-
Robotic surgery for management of endometrial cancer
-
Patient-initiated follow up for low-risk endometrial cancer
-
Use of ex-vivo models for personalising therapies
-
Dissecting the mechanism(s) of action of available chemopreventive agents such as aspirin and resveratrol
-
Investigating and exploiting metabolic vulnerabilities in carcinogenesis
-
Using circulating cell-free DNA for early detection of cancer
-
Determine which repetitive elements are active in precancerous and cancerous cells
-
Understanding what causes activation of repetitive elements
-
Establish activation of which repetitive elements plays functional roles in cancer
-
Investigate whether expression of repetitive elements has potential for early detection of cancer or as a predictor of response to therapy